MAP2K7 and non-small cell lung carcinoma: In addition, several on-going clinical trials are studying advanced NSCLC associated with the combination of CDK4/6 inhibitors with ERK, MEK, or mTOR inhibitors (NCT03170206, NCT02065063, NCT02857270, and NCT03454035) based on these and other promising preclinical data (3).